VIRal Pulmonary Infections in Older AGE

NCT07539103 | Not Yet Recruiting

• 1 other identifier: 2025-A01962-47
• Study Type: observational
• Target: 5,900
• Locations: 1 country
• Sites: 20

Brief Summary

Severe acute respiratory infections (SARIs) represent one of the leading causes of hospitalization and mortality worldwide. These infections are associated with substantial in-hospital mortality and often constitute a turning point in the medium-term prognosis of older patients and those with comorbid conditions. SARIs are most frequently of viral origin, involving well-known pathogens such as Orthomyxoviridae (influenza A and B viruses), Pneumoviridae \[(respiratory syncytial virus (RSV), human metapneumovirus (hMPV)\], Paramyxoviridae \[parainfluenza viruses (PIV)\], adenoviruses, or rhinoviruses, as well as emerging viruses such as pandemic influenza strains and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic. Age-related immune decline (immunosenescence) increases the risk of severe forms and related respiratory or cardiovascular complications. However, the prevalence and burden of the different viral etiologies of Severe acute respiratory infections (SARIs) in older adults remain limited and insufficiently characterized. The primary objective is to determine the proportion of viral respiratory infections attributable to polymerase chain reaction (PCR)-confirmed pathogen agents among hospitalized older subjects (≥60 years old).

Conditions

Viral Pulmonary Infections

Keywords

PCR; viral respiratory infections; viral respiratory pathogen; polymerase chain reaction

Outcome Measures

Primary Outcomes (1)

• Number of RT-PCR-confirmed positive cases for viral pathogen agents of interest among hospitalized older subjects (≥60 years old)

  At baseline

Secondary Outcomes (9)

• Number of RT-PCR-confirmed positive cases for each viral pathogen agent of interest among hospitalized older subjects

  From baseline to 3-month follow-up

• Number of RT-PCR-confirmed positive cases for each viral pathogen of interest among hospitalized older subjects according to the vaccination status

  From baseline to 3-month follow-up

• Number of RT-PCR -confirmed positive cases for each viral respiratory pathogen of interest among hospitalized older subjects according to the indication of PCR

  From baseline to 3-month follow-up

• Comparison of the prevalence of viral respiratory pathogen of interest among hospitalized older subjects by age groups

  From baseline to 3-month follow-up

• Hospital burden of acute respiratory infections

  From baseline to 3 month follow up

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Hospitalized older patients (≥60 years old) tested for PCR as part of standard of care (SoC). Subjects meeting the eligibility criteria will be invited to participate in the study.

You may qualify if:

• Hospitalized subjects aged ≥ 60 years
• A respiratory sample collected and tested by polymerase chain reaction (PCR) during hospitalisation as part of standard of care
• Note: Reasons for PCR:
• Patients with Severe acute respiratory infection (SARI)
• Patients with symptoms other than SARI
• Systematic PCR testing (in the context of clusters or during the winter season) \* Recent onset of at least one general symptom and at least one functional or physical respiratory sign
• General symptoms: fever (which may be absent in older patients), chills, sweating, headache, malaise, myalgia, arthralgia, fatigue, decline in general condition (asthenia, weight loss, anorexia, confusion, or dizziness), digestive disturbances.
• Respiratory signs: sore throat, rhinorrhoea (common cold), cough, wheezing, dyspnoea, chest pain, or recent auscultatory abnormalities (diffuse or focal).
• Subjects willing to participate, with a non-opposition form completed and signed by the qualified and trained healthcare professional responsible for providing the participant information
• Subject affiliated to a health insurance system

You may not qualify if:

• Subjects refusing to participate
• Subjects admitted to palliative care unit.
• Subjects under guardianship
• Any condition that, in the opinion of the investigator, may interfere with the aim of the study or wellbeing of the patient

Sponsors & Collaborators

• Gérond'if: lead

Study Sites (20)

CHU Bordeaux

Pessac, Bordeaux, 33604, France

Location

CHU Amiens Picardie

Amiens, 80054, France

Location

Centre Hospitalier Départemental Vendée_La Roche sur Yon

La Roche-sur-Yon, 85925, France

Location

CHU Nimes

Nîmes, 30029, France

Location

Hôpital St Antoine

Paris, 75012, France

Location

Hôpital Broca - APHP

Paris, France

Location

Hôpital Avicenne APHP

Bobigny, Île-de-France Region, 93000, France

Location

Hôpital Ambroise Paré-APHP

Boulogne-Billancourt, Île-de-France Region, 92100, France

Location

Hôpital Henri Mondor APHP

Créteil, Île-de-France Region, 94010, France

Location

Hôpital Corentin Celton APHP, Gérontologie 1

Issy-les-Moulineaux, Île-de-France Region, 92130, France

Location

Hôpital Corentin Celton APHP, Gérontologie 2

Issy-les-Moulineaux, Île-de-France Region, 92130, France

Location

Hôpital Charles Foix APHP

Ivry-sur-Seine, Île-de-France Region, 94200, France

Location

CH de Versailles

Le Chesnay, Île-de-France Region, 78157, France

Location

Hôpital Emile Roux APHP

Limeil-Brévannes, Île-de-France Region, 94450, France

Location

HEGP

Paris, Île-de-France Region, 75015, France

Location

Hôpital Bretonneau APHP

Paris, Île-de-France Region, 75016, France

Location

Hôpital Sainte Périne

Paris, Île-de-France Region, 75016, France

Location

Hôpital Lariboisière - APHP

Paris, Île-de-France Region, 75475, France

Location

Hôpital Bichat-APHP

Paris, Île-de-France Region, 75877, France

Location

Hôpital Paul Brousse APHP

Villejuif, Île-de-France Region, 94800, France

Location

Study Officials

• Olivier Hanon, MD PhD

  Geriatric Department, Broca hospital

  STUDY CHAIR

• LAUNAY Odile, MD PhD

  CIC de Vaccinologie Cochin Pasteur (CIC 1417)

  STUDY CHAIR

Central Study Contacts

Isabelle Dufour

CONTACT

+33 (0) 185781011; isabelle.dufour@gerondif.org

Prisca Lucas, PhD MPH

CONTACT

+33 (0)185737323; prisca.lucas@gerondif.org

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 1, 2026
• First Posted: April 20, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): September 30, 2028
• Study Completion (Estimated): September 30, 2028
• Last Updated: April 20, 2026

Record last verified: 2026-04

Locations

FR (20)